{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:50:11Z","timestamp":1791481811276,"version":"4.3.4"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2026-0122_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the birth prevalence and characterise the genotype, phenotype and management of children with congenital hyperinsulinism (CHI) in Western Australia\u00a0(WA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0122_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population-based retrospective study (2005\u20132024) of children with CHI was conducted at the tertiary paediatric centre in WA. Children with transient perinatal stress-induced HI and insulinoma were excluded. Data collection included clinical presentation, investigations and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0122_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The birth prevalence was 1 in 17,394 per 100,000 live births. Of 40 CHI cases, 65\u202f% were neonatal presentations. 32.5\u202f% were symptomatic with seizures in 15\u202f% of presentations. An aetiology was identified in 80\u202f% (n=32); 64.5\u202f% (n=21) had identified pathogenic gene variants with K-ATP channel defects in 14 children [ABCC8 (n=11), KCNJ11 (n=3)], the remainder had syndromic HI (n=11). 80\u202f% (n=32) responded to medical therapies; 78\u202f% (n=25) had an identified etiology. A pathogenic variant was identified in six of the seven infants with CHI which resolved in six\u202fmonths. Of those children who were diazoxide unresponsive (n=10), two stabilised on octreotide while eight (20\u202f%) required surgical management, which was curative in focal lesions (n=2). Secondary diabetes post pancreatectomy (n=6) occurred at a mean age of 5.25\u202fyears. The cohort had high continuous glucose monitoring uptake (92\u202f%) for glucose monitoring following subsidy with nine commenced in the neonatal period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0122_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of CHI in WA is higher than the reported European-ancestry population due to early genetic evaluation of newborns with CHI. Correlation between genotype and phenotype is consistent with literature and supports genetic investigation of infants with CHI to inform management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2026-0122","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:57:14Z","timestamp":1783072634000},"page":"854-865","source":"Crossref","is-referenced-by-count":0,"title":["Birth prevalence and characterisation of congenital hyperinsulinism in Western Australia over two decades"],"prefix":"10.1515","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1126-485X","authenticated-orcid":false,"given":"Adam J.","family":"Stafford-Bell","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes , Perth Children\u2019s Hospital , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2171-1288","authenticated-orcid":false,"given":"Amanda J.","family":"Hooper","sequence":"additional","affiliation":[{"name":"PathWest Laboratory Medicine WA , University of Western Australia , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Romans","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes , Perth Children\u2019s Hospital , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Flavel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes , Perth Children\u2019s Hospital , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-5925","authenticated-orcid":false,"given":"Shripad","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Neonatology , Perth Children\u2019s Hospital , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-271X","authenticated-orcid":false,"given":"Catherine S.Y.","family":"Choong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes , Perth Children\u2019s Hospital , Perth , WA , Australia"},{"name":"Faculty of Health & Medical Sciences , University of Western Australia , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-6340","authenticated-orcid":false,"given":"Sarah E.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Science , University of Exeter Medical School , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-1735","authenticated-orcid":false,"given":"Mary B.","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes , Perth Children\u2019s Hospital , Perth , WA , Australia"},{"name":"The Centre for Child Health Research , The Kids Research Institute, The University of Western Australia , Perth , WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2026100816572544626_j_jpem-2026-0122_ref_001","doi-asserted-by":"crossref","unstructured":"Giri, D, Hawton, K, Senniappan, S. Congenital hyperinsulinism: recent updates on molecular mechanisms, diagnosis and management. J\u00a0Pediatr Endocrinol Metab 2022;35:279\u201396. https:\/\/doi.org\/10.1515\/jpem-2021-0369.","DOI":"10.1515\/jpem-2021-0369"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_002","doi-asserted-by":"crossref","unstructured":"Pasquini, TLS, Lapidus, D, De Le\u00f3n, DD, Thornton, PS, Hood, D, Breit, J, et al.. The birth prevalence of congenital hyperinsulinism: a narrative review of the epidemiology of a rare disease. Horm Res Paediatr 2025;98:566\u201373. https:\/\/doi.org\/10.1159\/000539464.","DOI":"10.1159\/000539464"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_003","doi-asserted-by":"crossref","unstructured":"Mathew, PM, Young, JM, Abu-Osba, YK, Mulhern, BD, Hammoudi, S, Hamdan, JA, et al.. Persistent neonatal hyperinsulinism. Clin Pediatr (Phila) 1988;27:148\u201351. https:\/\/doi.org\/10.1177\/000992288802700307.","DOI":"10.1177\/000992288802700307"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_004","doi-asserted-by":"crossref","unstructured":"Lord, K, De Leon, DD. Hyperinsulinism in the neonate. Clin Perinatol 2018;45:61\u201374. https:\/\/doi.org\/10.1016\/j.clp.2017.10.007.","DOI":"10.1016\/j.clp.2017.10.007"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_005","doi-asserted-by":"crossref","unstructured":"Flanagan, SE, Kapoor, RR, Hussain, K. Genetics of congenital hyperinsulinemic hypoglycemia. Semin Pediatr Surg 2011;20:13\u20137. https:\/\/doi.org\/10.1053\/j.sempedsurg.2010.10.004.","DOI":"10.1053\/j.sempedsurg.2010.10.004"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_006","doi-asserted-by":"crossref","unstructured":"Snider, KE, Becker, S, Boyajian, L, Shyng, SL, MacMullen, C, Hughes, N, et al.. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J\u00a0Clin Endocrinol Metab 2013;98:E355\u201363. https:\/\/doi.org\/10.1210\/jc.2012-2169.","DOI":"10.1210\/jc.2012-2169"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_007","doi-asserted-by":"crossref","unstructured":"Wang, WY, Sun, Y, Zhao, WT, Wu, T, Wang, L, Yuan, TM, et al.. Congenital hyperinsulinism in China: a review of Chinese literature over the past 15\u00a0years. J\u00a0Clin Res Pediatr Endocrinol 2017;9:194\u2013201. https:\/\/doi.org\/10.4274\/jcrpe.3934.","DOI":"10.4274\/jcrpe.3934"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_008","doi-asserted-by":"crossref","unstructured":"Zenker, M, Mohnike, K, Palm, K. Syndromic forms of congenital hyperinsulinism. Front Endocrinol 2023;14:1013874. https:\/\/doi.org\/10.3389\/fendo.2023.1013874.","DOI":"10.3389\/fendo.2023.1013874"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_009","doi-asserted-by":"crossref","unstructured":"Rosenfeld, E, Ganguly, A, De Leon, DD. Congenital hyperinsulinism disorders: genetic and clinical characteristics. Am J Med Genet C Semin Med Genet 2019;181:682\u201392. https:\/\/doi.org\/10.1002\/ajmg.c.31737.","DOI":"10.1002\/ajmg.c.31737"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_010","doi-asserted-by":"crossref","unstructured":"Galcheva, S, Demirbilek, H, Al-Khawaga, S, Hussain, K. The genetic and molecular mechanisms of congenital hyperinsulinism. Front Endocrinol 2019;10:111. https:\/\/doi.org\/10.3389\/fendo.2019.00111.","DOI":"10.3389\/fendo.2019.00111"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_011","doi-asserted-by":"crossref","unstructured":"Banerjee, I, Salomon-Estebanez, M, Shah, P, Nicholson, J, Cosgrove, KE, Dunne, MJ. Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia. Diabet Med 2019;36:9\u201321. https:\/\/doi.org\/10.1111\/dme.13823.","DOI":"10.1111\/dme.13823"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_012","doi-asserted-by":"crossref","unstructured":"De Leon, DD, Arnoux, JB, Banerjee, I, Bergada, I, Bhatti, T, Conwell, LS, et al.. International guidelines for the diagnosis and management of hyperinsulinism. Horm Res Paediatr 2024;97:279\u201398. https:\/\/doi.org\/10.1159\/000531766.","DOI":"10.1159\/000531766"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_013","doi-asserted-by":"crossref","unstructured":"Burnside, MJ, Stafford-Bell, A, Romans, R, Moller, M, Choong, CS, Abraham, MB. Continuous subcutaneous octreotide infusion in congenital hyperinsulinism: practical application and insights in infancy and early childhood. J\u00a0Diabetes Metab Disord 2025;24:222. https:\/\/doi.org\/10.1007\/s40200-025-01709-2.","DOI":"10.1007\/s40200-025-01709-2"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_014","doi-asserted-by":"crossref","unstructured":"Senniappan, S, Alexandrescu, S, Tatevian, N, Shah, P, Arya, V, Flanagan, S, et al.. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N\u00a0Engl J Med 2014;370:1131\u20137. https:\/\/doi.org\/10.1056\/nejmoa1310967.","DOI":"10.1056\/NEJMoa1310967"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_015","doi-asserted-by":"crossref","unstructured":"Burnside, MJ, Benitez-Aguirre, P, Romans, R, Gehrmann, F, Velayutham, V, Alexander, A, et al.. Effective and safe use of sirolimus in hyperinsulinemic hypoglycaemia refractory to medical and surgical therapy: a case series and review of literature. J\u00a0Pediatr Endocrinol Metab 2024;37:900\u201311. https:\/\/doi.org\/10.1515\/jpem-2024-0348.","DOI":"10.1515\/jpem-2024-0348"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_016","doi-asserted-by":"crossref","unstructured":"Bennett, JJ, Saint-Martin, C, Neumann, B, M\u00e4nnist\u00f6, JME, Houghton, JAL, Empting, S, et al.. Non-coding cis-regulatory variants in HK1 cause congenital hyperinsulinism with variable disease severity. Genome Med 2025;17:17. https:\/\/doi.org\/10.1186\/s13073-025-01440-w.","DOI":"10.1186\/s13073-025-01440-w"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_017","doi-asserted-by":"crossref","unstructured":"Cabezas, OR, Flanagan, SE, Stanescu, H, Garc\u00eda-Mart\u00ednez, E, Caswell, R, Lango-Allen, H, et al.. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2. J\u00a0Am Soc Nephrol 2017;28:2529\u201339. https:\/\/doi.org\/10.1681\/asn.2016121312.","DOI":"10.1681\/ASN.2016121312"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_018","doi-asserted-by":"crossref","unstructured":"Flanagan, SE, Xie, W, Caswell, R, Damhuis, A, Vianey-Saban, C, Akcay, T, et al.. Next-generation sequencing reveals deep intronic cryptic ABCC8 and HADH splicing founder mutations causing hyperinsulinism by pseudoexon activation. Am J Hum Genet 2013;92:131\u20136. https:\/\/doi.org\/10.1016\/j.ajhg.2012.11.017.","DOI":"10.1016\/j.ajhg.2012.11.017"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_019","doi-asserted-by":"crossref","unstructured":"Otonkoski, T, Jiao, H, Kaminen-Ahola, N, Tapia-Paez, I, Ullah, MS, Parton, LE, et al.. Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. Am J Hum Genet 2007;81:467\u201374. https:\/\/doi.org\/10.1086\/520960.","DOI":"10.1086\/520960"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_020","doi-asserted-by":"crossref","unstructured":"Wakeling, MN, Owens, NDL, Hopkinson, JR, Johnson, MB, Houghton, JAL, Dastamani, A, et al.. Non-coding variants disrupting a tissue-specific regulatory element in HK1 cause congenital hyperinsulinism. Nat Genet 2022;54:1615\u201320. https:\/\/doi.org\/10.1038\/s41588-022-01204-x.","DOI":"10.1038\/s41588-022-01204-x"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_021","doi-asserted-by":"crossref","unstructured":"Laver, TW, De Franco, E, Johnson, MB, Patel, KA, Ellard, S, Weedon, MN, et al.. SavvyCNV: genome-wide CNV calling from off-target reads. PLoS Comput Biol 2022;18:e1009940. https:\/\/doi.org\/10.1371\/journal.pcbi.1009940.","DOI":"10.1371\/journal.pcbi.1009940"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_022","doi-asserted-by":"crossref","unstructured":"Flanagan, SE, Lazaridi, IA, M\u00e4nnist\u00f6, JME, Bennett, JJ, Kalyon, O, Johnson, MB, et al.. Large copy number variants are an important cause of congenital hyperinsulinism that should be screened for during routine testing. Front Endocrinol 2025;16:1514916. https:\/\/doi.org\/10.3389\/fendo.2025.1514916.","DOI":"10.3389\/fendo.2025.1514916"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_023","doi-asserted-by":"crossref","unstructured":"Yau, D, Laver, TW, Dastamani, A, Senniappan, S, Houghton, JAL, Shaikh, G, et al.. Using referral rates for genetic testing to determine the incidence of a rare disease: the minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389. PLoS One 2020;15:e0228417. https:\/\/doi.org\/10.1371\/journal.pone.0228417.","DOI":"10.1371\/journal.pone.0228417"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_024","unstructured":"CAHS [Internet]. [cited 19th December]. Available from: https:\/\/cahs.health.wa.gov.au\/\u223c\/media\/HSPs\/CAHS\/Documents\/Health-Professionals\/Neonatology-guidelines\/Hypoglycaemia.pdf?thn=0."},{"key":"2026100816572544626_j_jpem-2026-0122_ref_025","doi-asserted-by":"crossref","unstructured":"Thornton, PS, Stanley, CA, De Leon, DD, Harris, D, Haymond, MW, Hussain, K, et al.. Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J\u00a0Pediatr 2015;167:238\u201345. https:\/\/doi.org\/10.1016\/j.jpeds.2015.03.057.","DOI":"10.1016\/j.jpeds.2015.03.057"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_026","doi-asserted-by":"crossref","unstructured":"Raicevic, M, Milenkovic, T, Hussain, K, Djordjevic, M, Martic, J, Todorovic, S, et al.. Clinical and genetic characteristics of patients with congenital hyperinsulinism in 21\u00a0non-consanguineous families from Serbia. Eur J Pediatr 2021;180:2815\u201321. https:\/\/doi.org\/10.1007\/s00431-021-04051-w.","DOI":"10.1007\/s00431-021-04051-w"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_027","doi-asserted-by":"crossref","unstructured":"Yavas Abali, Z, Bas, F, Houghton, JAL, Abali, S, Karakilic Ozturan, E, Gulec, C, et al.. Comprehensive clinical and molecular characterization with long-term outcomes in 40 patients with congenital hyperinsulinism. Endocrine 2025;89:416\u201328. https:\/\/doi.org\/10.1007\/s12020-025-04244-5.","DOI":"10.1007\/s12020-025-04244-5"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_028","doi-asserted-by":"crossref","unstructured":"M\u00e4nnist\u00f6, JME, J\u00e4\u00e4skel\u00e4inen, J, Otonkoski, T, Huopio, H. Long-term outcome and treatment in persistent and transient congenital hyperinsulinism: a Finnish population-based study. J\u00a0Clin Endocrinol Metab 2021;106:e1542\u20131. https:\/\/doi.org\/10.1210\/clinem\/dgab024.","DOI":"10.1210\/clinem\/dgab024"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_029","doi-asserted-by":"crossref","unstructured":"Kapoor, RR, Flanagan, SE, Arya, VB, Shield, JP, Ellard, S, Hussain, K. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol 2013;168:557\u201364. https:\/\/doi.org\/10.1530\/eje-12-0673.","DOI":"10.1530\/EJE-12-0673"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_030","doi-asserted-by":"crossref","unstructured":"Maiorana, A, Tagliaferri, F, Iannuzzi, R, Canciani, G, Bernabei, SM, Campana, C, et al.. Congenital hyperinsulinism of a large Italian cohort: a retrospective study. Horm Res Paediatr 2025;98:478\u201390. https:\/\/doi.org\/10.1159\/000538943.","DOI":"10.1159\/000538943"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_031","doi-asserted-by":"crossref","unstructured":"Globa, E, Christesen, HT, Mortensen, MB, Houghton, JAL, Nielsen, AL, Detlefsen, S, et al.. Congenital hyperinsulinism in the Ukraine: a 10-year national study. Front Endocrinol 2024;15:1497579. https:\/\/doi.org\/10.3389\/fendo.2024.1497579.","DOI":"10.3389\/fendo.2024.1497579"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_032","doi-asserted-by":"crossref","unstructured":"Lobotkov\u00e1, D, Mi\u0148ov\u00e1, M, Ferenczov\u00e1, J, Dankov\u010d\u00edkov\u00e1, A, \u0160evecov\u00e1, M, Blankenstein, O, et al.. Nationwide epidemiology and genetic background of persistent nonsyndromic congenital hyperinsulinism in Slovakia. Horm Res Paediatr 2025:1\u201312. https:\/\/doi.org\/10.1159\/000549591.","DOI":"10.1159\/000549591"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_033","doi-asserted-by":"crossref","unstructured":"Greeley, SAW, Polak, M, Nj\u00f8lstad, PR, Barbetti, F, Williams, R, Castano, L, et al.. ISPAD clinical practice consensus guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2022;23:1188\u2013211. https:\/\/doi.org\/10.1111\/pedi.13426.","DOI":"10.1111\/pedi.13426"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_034","doi-asserted-by":"crossref","unstructured":"Huopio, H, Otonkoski, T, Vauhkonen, I, Reimann, F, Ashcroft, FM, Laakso, M. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003;361:301\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(03)12325-2.","DOI":"10.1016\/S0140-6736(03)12325-2"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_035","doi-asserted-by":"crossref","unstructured":"Kapoor, RR, Flanagan, SE, James, CT, McKiernan, J, Thomas, AM, Harmer, SC, et al.. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8\/KCNJ11 mutations. Diabetologia 2011;54:2575\u201383. https:\/\/doi.org\/10.1007\/s00125-011-2207-4.","DOI":"10.1007\/s00125-011-2207-4"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_036","doi-asserted-by":"crossref","unstructured":"Salomon-Estebanez, M, Flanagan, SE, Ellard, S, Rigby, L, Bowden, L, Mohamed, Z, et al.. Conservatively treated congenital hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time. Orphanet J Rare Dis 2016;11:163. https:\/\/doi.org\/10.1186\/s13023-016-0547-3.","DOI":"10.1186\/s13023-016-0547-3"},{"key":"2026100816572544626_j_jpem-2026-0122_ref_037","doi-asserted-by":"crossref","unstructured":"Vijayanand, S, Stevenson, PG, Grant, M, Choong, CS, Davis, EA, Abraham, MB. The utility of continuous glucose monitoring systems in the management of children with persistent hypoglycaemia. J\u00a0Pediatr Endocrinol Metab 2021;34:1567\u201372. https:\/\/doi.org\/10.1515\/jpem-2021-0414.","DOI":"10.1515\/jpem-2021-0414"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0122\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0122\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:57:48Z","timestamp":1791478668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0122\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,9,25]]}},"alternative-id":["10.1515\/jpem-2026-0122"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2026-0122","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}